Copyright
©The Author(s) 2022.
World J Gastrointest Pharmacol Ther. Jul 5, 2022; 13(4): 57-66
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.57
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.57
Variable | UC (n = 68) | Control (n = 66) | P value |
Age (yr), median (IR) | 39.0 (31.0-44.8) | 36.5 (29.0-43.0) | 0.484 |
Sex (female), n (%) | 42 (61.8) | 39 (59.1) | 0.867 |
Smoking (yes), n (%) | 2 (2.9) | 4 (6.1) | 0.437 |
Regular physical activity (yes), n (%) | 16 (23.5) | 15 (22.7) | 1.000 |
Duration of illness (yes), median (IR) | 5.0 (2.0-8.0) | ||
Disease remission (yes), n (%) | 66 (97.1) | ||
Intestinal resection history (yes), n (%) | 2 (2.9) | ||
Extent of disease, n (%) | |||
Proctitis | 13 (19.1) | ||
Left colitis | 25 (36.8) | ||
Extensive colitis | 30 (44.1) | ||
Use of glucocorticoids (yes), n (%) | 12 (17.6) | ||
Use ≥ 3 mo (yes), n (%) | 8 (66.7) | ||
Accumulated dose of glucocorticoids (g), median (IR) | 1.7 (1.2-2.5) | ||
Calcium supplement (yes), n (%) | 3 (4.4) | 0 (0) | 0.245 |
Vit D supplement (yes), n (%) | 5 (7.4) | 0 (0) | 0.058 |
Serum calcium (mmol/L), median (IR) | 2.3 (2.2-2.4) | 2.4 (2.3-2.4) | 0.065 |
Serum albumin (g/dL), median (IR) | 4.3 (4.1-4.5) | 4.4 (4.1-4.6) | 0.801 |
C-RP mg/dL, median (IR) | 1.4 (0.6-5.2) | 5.0 (1.0-6.2) | 0.004 |
BMI (kg/m2), median (IR) | 23.7 (20.6-26.5) | 26.3 (22.8-29.0) | 0.16 |
BMI classification, n (%) | 0.020 | ||
Thinness | 5 (7.4) | 1 (1.5) | |
Eutrophy | 40 (58.8) | 26 (39.4) | |
Overweight | 16 (23.5) | 28 (42.4) | |
Obesity | 7 (10.3) | 11 (16.7) | |
WC (cm), median (IR) | 80.5 (72.0-89.1) | 84.6 (79.7-93.7) | 0.156 |
LBM (kg), median (IR) | 40.1 (34.5-49.4) | 41.5 (35.3-52.2) | 0.604 |
BF (kg), median (IR) | 17.8 (11.5-22.6) | 23.2 (17.8-28.4) | 0.001 |
BF (%), median (IR) | 32.9 (23.7-37.6) | 34.8 (28.1-42.3) | 0.168 |
TBF (kg), median (IR) | 8.6 (6.3-12.5) | 12.8 (7.8-16.5) | 0.354 |
BMD (g/cm2), median (IR) | |||
Femoral neck | 0.99 (0.90-1.07) | 1.06 (0.96-1.15) | 0.120 |
Lumbar spine | 1.16 (1.08-1.26) | 1.21 (1.13-1.31) | 0.120 |
Total body | 1.17 (1.11-1.24) | 1.22 (1.19-1.29 | 0.000 |
Variable | Normal BMD (n = 40) | Low BMD (n = 28) | P value |
Age (yr), median (IR) | 37.5 (30.0-43.0) | 40.0 (32.5-46.0) | 0.193 |
Age group, n (%) | |||
< 45 yr | 31 (77.5) | 20 (71.4) | 0.57 |
≥ 45 yr | 9 (22.5) | 8 (28.6) | |
Sex, n (%) | |||
Male | 11 (27.5) | 15 (53.6) | 0.03 |
Female | 29 (72.5) | 13 (46.4) | |
Regular physical activity, n (%) | |||
No | 27 (67.5) | 25 (89.3) | 0.04 |
Yes | 13 (32.5) | 3 (10.7) | |
Duration of illness (yr), median (IR) | 5.0 (2.0-9.0) | 4.5 (1.2-6.7) | 0.98 |
Extent of disease, n (%) | |||
Proctitis | 12 (30.0) | 1 (3.6) | 0.01 |
Left colitis | 11 (27.5) | 14 (50.0) | |
Extensive colitis | 17 (42.5) | 13 (46.4) | |
Use of glucocorticoids, n (%) | |||
No | 33 (84.6) | 22 (78.6) | 0.75 |
Yes | 6 (15.4) | 6 (21.4) | |
Use of glucocorticoids ≥ 3 mo, n (%) | |||
No | 3 (50.0) | 1 (16.7) | 0.54 |
Yes | 3 (50.0) | 5 (83.3) | |
Accumulated dose of glucocorticoids (g), median (IR) | 1.8 (1.3-2.3) | 1.5 (1.1-3.5) | 0.55 |
Serum calcium (mmol/L), median (IR) | 2.3 (2.3-2.4) | 2.2 (2.2-2.3) | 0.03 |
Serum albumin (g/dL), median (IR) | 4.4 (4.1-4.6) | 4.3 (4.0-4.5) | 0.57 |
PCR mg/dL, median (IR) | 3.1 (0.9-6.1) | 1.6 (1.6-6.3) | 0.56 |
Variable | Prevalence of low BMD, n (%) | PR (95%CI) | P value | |
Sex | ||||
Female | 15 | 57.7 | 1.00 | |
Male | 13 | 31.0 | 1.86 (1.07 – 3.26) | 0.029 |
Age group | ||||
< 45 yr | 20 | 39.2 | 1.00 | |
≥ 45 yr | 8 | 47.1 | 1.38 (0.46 – 4.16) | 0.583 |
Regular physical activity | ||||
Yes | 3 | 18.8 | 1.00 | |
No | 25 | 48.1 | 2.56 (0.89 – 7.39) | 0.081 |
Steroid use | ||||
No | 23 | 38.3 | 1.00 | |
Yes | 5 | 62.5 | 1.63 (0.87 – 3.05) | 0.126 |
Steroid use | ||||
< 3 mo | 1 | 25.0 | 1.00 | |
≥ 3 mo | 5 | 62.5 | 2.50 (0.42 – 14.8) | 0.313 |
BMI classification | ||||
Not overweight | 23 | 51.1 | 1.00 | |
Overweight | 5 | 21.7 | 0.43 (0.19 – 0.97) | 0.043 |
WC classification | ||||
Normal | 21 | 52.5 | 1.00 | |
Elevated | 6 | 23.1 | 0.44 (0.21 – 0.94) | 0.034 |
BF classification (%) | ||||
Normal | 10 | 45.5 | 1.00 | |
Elevated | 18 | 39.1 | 0.86 (0.48 – 1.54) | 0.614 |
- Citation: Lopes MB, Lyra AC, Rocha R, Coqueiro FG, Lima CA, de Oliveira CC, Santana GO. Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis. World J Gastrointest Pharmacol Ther 2022; 13(4): 57-66
- URL: https://www.wjgnet.com/2150-5349/full/v13/i4/57.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v13.i4.57